Precision medicine in breast cancer

Reality or utopia?

Ali Bettaieb, Catherine Paul, Stéphanie Plenchette, Jingxuan Shan, Lotfi Chouchane, François Ghiringhelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.

Original languageEnglish
Article number139
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Utopias
Precision Medicine
Medicine
Breast Neoplasms
Therapeutics
Tumors
Molecular Biology
Neoplasms
Physicians
Mutation
Research

Keywords

  • Breast cancer
  • Chemotherapy
  • HER2+
  • Immunotherapy
  • Molecular subtypes
  • Phase III clinical trials
  • Precision medicine
  • Triple-negative
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Precision medicine in breast cancer : Reality or utopia? / Bettaieb, Ali; Paul, Catherine; Plenchette, Stéphanie; Shan, Jingxuan; Chouchane, Lotfi; Ghiringhelli, François.

In: Journal of Translational Medicine, Vol. 15, No. 1, 139, 01.01.2017.

Research output: Contribution to journalArticle

Bettaieb, Ali ; Paul, Catherine ; Plenchette, Stéphanie ; Shan, Jingxuan ; Chouchane, Lotfi ; Ghiringhelli, François. / Precision medicine in breast cancer : Reality or utopia?. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.
@article{9289fc3161ba4c66862400921fe08663,
title = "Precision medicine in breast cancer: Reality or utopia?",
abstract = "Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.",
keywords = "Breast cancer, Chemotherapy, HER2+, Immunotherapy, Molecular subtypes, Phase III clinical trials, Precision medicine, Triple-negative, Tumor heterogeneity",
author = "Ali Bettaieb and Catherine Paul and St{\'e}phanie Plenchette and Jingxuan Shan and Lotfi Chouchane and Fran{\cc}ois Ghiringhelli",
year = "2017",
month = "1",
day = "1",
doi = "10.1186/s12967-017-1239-z",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Precision medicine in breast cancer

T2 - Reality or utopia?

AU - Bettaieb, Ali

AU - Paul, Catherine

AU - Plenchette, Stéphanie

AU - Shan, Jingxuan

AU - Chouchane, Lotfi

AU - Ghiringhelli, François

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.

AB - Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.

KW - Breast cancer

KW - Chemotherapy

KW - HER2+

KW - Immunotherapy

KW - Molecular subtypes

KW - Phase III clinical trials

KW - Precision medicine

KW - Triple-negative

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85027579006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027579006&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1239-z

DO - 10.1186/s12967-017-1239-z

M3 - Article

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 139

ER -